The article argues that AI will revolutionize drug discovery long before it can streamline clinical development, creating an abundance of candidate molecules but leaving patient trials as the main constraint. As discovery becomes commoditized and more assets target the same biology, real value will hinge on predictive toxicity, clinical efficacy, and strategic trial design.

• Drug candidate pipelines have doubled in the past decade but novel FDA approvals stayed flat at ~50/year, proving clinical development—not discovery—is the real bottleneck.
• Preclinical assets license for tens of millions, but value jumps to hundreds of millions or low-billions post-Phase 2 proof of concept—a premium set to shrink as AI floods the pipeline with candidates.
• Competition per target is already intense (100+ programs on targets like PD-1/GLP-1) and could double or triple by 2030, making individual molecules less rare and pushing investors to demand better translational data and trial design.
• AI excels at data-rich, fast-feedback problems (virtual screening, protein folding) but struggles with messy, high-variability clinical questions (endpoint selection, immune response prediction, adaptive trials)—so real value will shift to whoever masters those still-slow areas.

Anthropic cut off access to its Mythos 5 and Fable 5 AI models to comply with new US export controls. Elon Musk became the world’s first trillionaire after SpaceX shares surged in its IPO. The update also covers a CRISPR method that targets “undruggable” cancers and the first working nuclear clocks from Chinese and European teams.

• Anthropic fully cut off its Mythos 5 and Fable 5 models to comply with new US export controls barring their use outside the US.
• Elon Musk became the first trillionaire after SpaceX's IPO share price hit $135, pushing his net worth past $1 trillion—over 3% of US GDP.
• A new CRISPR method targets and destroys cells with a tumor-suppressor mutation found in up to half of all cancers (70-90% of hard-to-treat cases), offering a faster path to treatment than small-molecule drugs.
• Chinese and European teams each independently built working nuclear clocks using thorium-229, solving the laser wavelength problem with different approaches (higher power vs. denser crystal matrix).

Today’s TLDR rundown covers SpaceX’s IPO oversubscribed by more than four times, OpenAI prepping steep token-price cuts ahead of an AI price war with Anthropic, and Stack Overflow’s new API-first knowledge platform for AI agents. Plus quick briefs on gene-therapy vision reversal and China’s first commercial brain implant.

• SpaceX's IPO was oversubscribed more than 4x, selling 555.6M shares at $135 each—set to be the biggest IPO in U.S. history if it holds
• OpenAI is preparing to cut token prices to match Anthropic, risking thinner margins for both as they burn cash on GPU costs
• Stack Overflow launched an API-first "Stack Overflow for Agents" platform using multi-agent loops and trust scores to keep docs accurate for AI agents
• China approved NeuraMatrix's NEO brain-computer interface for commercial use, putting it ahead of Neuralink's N1, which remains stuck in U.S. research trials

AWS introduced Amazon Bio Discovery, an AI-driven platform that lets researchers run complex drug-design workflows without coding. It provides a library of biological foundation models, an AI agent for workflow setup and analysis, and links to lab partners for synthesis and testing, cutting months of work down to weeks.

• AWS launched Amazon Bio Discovery, a no-code AI platform letting scientists run drug-design workflows using foundation models plus an AI agent, cutting months of research into weeks.
• In a Memorial Sloan Kettering/Twist Bioscience collaboration, nearly 300,000 AI-designed antibodies were narrowed to 100,000 for physical lab testing.
• Bayer, Broad Institute and Voyager Therapeutics are early adopters, and 19 of the top 20 global pharma companies already use AWS cloud services.
• AWS is separately partnering with Boston Consulting Group and Merck on an AI tool to improve clinical trial site selection.

Boltz is launching a transformative approach to drug design and biological research by combining AI and open science, enabling over 100,000 scientists to innovate faster. With a newly raised $28 million seed round and a partnership with Pfizer, Boltz aims to break down barriers in drug development through open-source models and accessible computational tools.

• Boltz raised a $28 million seed round and partnered with Pfizer to advance open-source drug design models.
• Over 100,000 scientists are already using Boltz's tools, positioning it as a widely-adopted open-science alternative to closed AI drug discovery platforms.
• The core bet is that open-source, freely accessible AI models can accelerate biological research and drug development faster than proprietary approaches.